Atezolimab plus bevacizumab prompts strong early response in unresectable HCC

Key clinical point: A combination of atezolizumab plus bevacizumab showed therapeutic potential for adults with unresectable HCC, as patients showed a strong initial therapeutic response; the most common adverse events were appetite loss, fatigue, and urine protein.

Major finding: After 6 weeks, the overall objective response rate for early tumor shrinkage was 10.6% and the disease control rate was 79.6%; results were similar for the subset of patients with no prior history of systemic treatment (9.7% and 12.2%).

Study details: The data come from a retrospective study of 171 adults with unresectable hepatocellular carcinoma who were treated with a combination of atezolizumab plus bevacizumab; 75 of these had no prior history of systemic treatment.

Disclosures: The study was supported by the Institutional Ethics Committee of Ehime Prefectural Central Hospital. The researchers had no financial conflicts to disclose.

Source: Hiraoka A et al. Cancer Rep. 2021 Jun 11. doi: 10.1002/cnr2.1464.